Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0HISTV
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AVE-9633
|
|||||
| Synonyms |
AVE 9633; AVE-9633; AVE96 33; AVE9633; Anti-CD33 TAP; Anti-CD33-DM4 immunoconjugate; IMGN-633; huMY96DM4; huMy9-6-DM4
Click to Show/Hide
|
|||||
| Organization |
ImmunoGen, Inc.; Sanofi
|
|||||
| Drug Status |
Phase 1 (Terminated)
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
3.5
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-CD33 mAb huMy9-6
|
Antibody Info | ||||
| Antigen Name |
Myeloid cell surface antigen CD33 (CD33)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM4
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
| Combination Type |
ravtansine
|
|||||
| Puchem SID | ||||||
| Drugbank ID | ||||||
| ChEBI ID | ||||||
